Ensysce Biosciences(ENSC) - 2025 Q2 - Quarterly Results

Exhibit 99.1 Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates Initiates Critical Milestone, Launching Phase 3 Trial of PF614 to Advance Next-Generation Opioid Therapy Toward Regulatory Approval Receives $5.3 Million Installment from NIDA To Support Overdose Protection Program The Company's lead product, PF614, is a Trypsin-Activated Abuse Protection (TAAP) extended-release oxycodone and a potential "next generation" analgesic to treat severe pain. PF614's TAAP che ...